4-(3-硝基苯基)-3-氧代丁酸乙酯 | 116904-71-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-硝基苯基)-3-氧代丁酸乙酯
• 英文名称: ethyl 3-oxo-4-(3-nitrophenyl)butanoate
• 英文别名: ethyl 4-(3-nitrophenyl)-3-oxobutanoate
• CAS: 116904-71-3
• 化学式: C₁₂H₁₃NO₅
• 分子量: 251.239
• InChiKey: GSKBATUYMHEXQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  89.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  4-(3-硝基苯基)-3-氧代丁酸乙酯 在 锂硼氢 、 三溴化磷 、 三乙胺 作用下， 以 四氢呋喃 、 异丙醚 为溶剂， 反应 5.67h， 生成 5-bromomethyl-4-<(3-nitrophenyl)methyl>-2-phenylpyrimidine
  参考文献：
  名称：

  Studies on Cerebral Protective Agents. VI. Synthesis of Novel 4-(4-Nitrobenzoyl)pyrimidine and Related Compounds with Anti-anoxic Activity.

  摘要：

  制备了新型嘧啶衍生物，在芳基和 C-4 位嘧啶核之间具有连接，并在小鼠中测试了其抗缺氧 (AA) 活性。其中，5-(4-甲基哌嗪-1-基羰基)-4-(4-硝基苯甲酰基)-2-苯基嘧啶(2f，FR76659)具有显着的AA活性(10-100 mg/kg，i.p.)且急性毒性低( LD50>1000 mg/kg，腹腔注射）。检查了该系列化合物的 AA 活性的构效关系。

  DOI：

  10.1248/cpb.42.1279
• 作为产物：
  描述：

  ethyl potassium malonate 、 1-(1H-咪唑-1-基)-2-(3-硝基苯基)乙酮 在 三乙胺 、 magnesium chloride 作用下， 生成 4-(3-硝基苯基)-3-氧代丁酸乙酯
  参考文献：
  名称：

  5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones:  Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives

  摘要：

  Molecular modeling analysis of compounds belonging to the recently published series of dihydroalkoxy-benzyl-oxopyrimidines (DABOs), such as S-DABOs and DATNOs, gave support to the design of new 2,6-disubstituted benzyl-DABO derivatives as highly potent and specific inhibitors of the HIV-1 reverse transcriptase (RT). To follow up on the novel DABO derivatives, we decided to investigate the effect of electron-withdrawing substituents in the benzyl unit of the S-DABO skeleton versus their anti-HIV-1 activity. Such chemical modifications impacted the inhibitory activity, especially when two halogen units were introduced at positions 2 and 6 in the phenyl portion of the benzyl group bound to C-6 of the pyrimidine ring. Various 5-alkyl-2-(alkyl(or cycloalkyl)thio)-6-(2,B-dichloro(or 2, 6-difluoro)phenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones were then synthesized and tested as anti-HIV-1 agents in both cell-based and enzyme (recombinant reverse transcriptase, rRT) assays. Among the various mono- and disubstituted phenyl derivatives, the most potent were those containing a 6-(2,6-difluorophenylmethyl) substituent (F-DABOs), which showed EC50's ranging between 40 and 90 nM and selectivity indexes up to greater than or equal to 5000. An excellent correlation was found between EC50 and IC50 values which confirmed that these compounds act as inhibitors of the HIV-1 RT. The structure-activity relationships of the newly synthesized pyrimidinones are presented herein.

  DOI：

  10.1021/jm980260f

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• Studies on Cerebral Protective Agents. VII. Synthesis of Novel 4-Arylazole Derivatives with Anti-anoxic Activity.
  作者：Mitsuru OHKUBO、Atsushi KUNO、Hiroyoshi SAKAI、Hisashi TAKASUGI

  DOI：10.1248/cpb.43.947

  日期：——

  Novel 4-arylazole (i.e. thiazole, oxazole, and imidazole) derivatives, possessing an amino moiety at the C-5 position of the azole ring, were prepared and tested for anti-anoxic (AA) activity in mice. Among them, 5-(4-methylpiperazin-1-yl)methyl-4-(3-nitrophenyl)-2-phenylthiazole (3b, FR75094) possessed significant AA activity (10 mg/kg, i.p. and 100 mg/kg, p.o., respectively), and was also effective on anti-lipid peroxidation (ALP) assay and inhibited arachidonate-induced cerebral edema in rats. Structure-activity relationships in regard to AA activity of this series of compounds are discussed.

  新型4元氮杂环（即噻唑、噁唑和咪唑）衍生物，其氮杂环第5位具有氨基基团，被制备并用于测试对小鼠的抗缺氧（AA）活性。其中，5-（4-甲基哌嗪-1-基）甲基-4-（3-硝基苯基）-2-苯基噻唑（3b，FR75094）显示出显著的AA活性（分别为10 mg/kg腹腔注射和100 mg/kg口服），并且在抗脂质过氧化（ALP）测试中有效，抑制了花生四烯酸引起的大鼠脑水肿。讨论了这一系列化合物在AA活性方面的构效关系。
• Rao, D. Chandra; Reddy, D. Kumar; Shekhar, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2014, vol. 53, # 3, p. 356 - 358
  作者：Rao, D. Chandra、Reddy, D. Kumar、Shekhar、Chinababu、Rao, Ch. Bhujanga、Venkateswarlu

  DOI：——

  日期：——
• BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1292585A1

  公开（公告）日：2003-03-19
• [EN] BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS<br/>[FR] BENZOXAZEPINONES ET LEUR UTILISATION COMME INHIBITEURS DE LA SQUALENE SYNTHASE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001098282A1

  公开（公告）日：2001-12-27

  There is disclosed a compound represented by formula (I), wherein R1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X?1-X2-Ar-X3-X4¿-COOH (wherein X?1 and X4¿ are a bond or alkylene group, X?2 and X3¿ are a bond, -O-, -S-, Ar is divalent aromatic group , etc.), R2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.